WuXi Biologics To Invest $60M For Its First Manufacturing Facility In United States

Login to View

WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY

Please enter your comment!
Please enter your name here